CNS Pharmaceuticals Inc (NASDAQ:CNSP) — Market Cap & Net Worth
Market Cap & Net Worth: CNS Pharmaceuticals Inc (CNSP)
CNS Pharmaceuticals Inc (NASDAQ:CNSP) has a market capitalization of $6.93 Million ($6.93 Million) as of June 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27901 globally and #5681 in its home market, demonstrating a -5.20% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CNS Pharmaceuticals Inc's stock price $4.74 by its total outstanding shares 1461449 (1.46 Million). Review CNS Pharmaceuticals Inc total liabilities to assess the company's total debt and financial obligations.
CNS Pharmaceuticals Inc Market Cap History: 2019 to 2026
CNS Pharmaceuticals Inc's market capitalization history from 2019 to 2026. Data shows change from $8.66 Billion to $6.93 Million (-66.77% CAGR).
Index Memberships
CNS Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.44 Trillion | 0.00% | #811 of 976 |
|
NASDAQ Composite
IXIC
|
$41.39 Trillion | 0.00% | #2609 of 3165 |
Weight: CNS Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
CNS Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CNS Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CNSP by Market Capitalization
Companies near CNS Pharmaceuticals Inc in the global market cap rankings as of June 16, 2026.
Key companies related to CNS Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.36 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $450.46 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.36 Billion | $614.98 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €259.20 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €761.20 |
CNS Pharmaceuticals Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, CNS Pharmaceuticals Inc's market cap moved from $8.66 Billion to $ 6.93 Million, with a yearly change of -66.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $6.93 Million | -9.71% |
| 2025 | $7.67 Million | +4260.47% |
| 2024 | $175.96K | -99.81% |
| 2023 | $92.80 Million | -47.08% |
| 2022 | $175.37 Million | -88.60% |
| 2021 | $1.54 Billion | -60.56% |
| 2020 | $3.90 Billion | -54.94% |
| 2019 | $8.66 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of CNS Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.93 Million USD |
| MoneyControl | $6.93 Million USD |
| MarketWatch | $6.93 Million USD |
| marketcap.company | $6.93 Million USD |
| Reuters | $6.93 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CNS Pharmaceuticals Inc
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate ca… Read more